2020
Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial
Danne T, Tamborlane WV, Malievsky OA, Franco DR, Kawamura T, Demissie M, Niemoeller E, Goyeau H, Wardecki M, Battelino T. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial. Diabetes Care 2020, 43: 1512-1519. PMID: 32430458, PMCID: PMC7305011, DOI: 10.2337/dc19-1926.Peer-Reviewed Original Research
2013
Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis
Cengiz E, Connor CG, Ruedy KJ, Beck RW, Kollman C, Klingensmith GJ, Tamborlane WV, Lee JM, Haller MJ, Consortium F. Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis. Pediatric Diabetes 2013, 15: 287-293. PMID: 23944865, PMCID: PMC3844085, DOI: 10.1111/pedi.12068.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDrug MonitoringFemaleFollow-Up StudiesGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsIncidenceInfantInsulinKaplan-Meier EstimateMaleProportional Hazards ModelsProspective StudiesUnited StatesConceptsPediatric Diabetes ConsortiumDiabetic ketoacidosisClinical outcomesNatural historyFirst yearCourse of T1DDiagnosis of T1D.Onset of T1DTime of diagnosisSevere hypoglycemic eventsType 1 diabetesMean HbA1cMulticenter studyHypoglycemic eventsClinical measuresLarge cohortIntervention studiesDiagnosisFuture interventionsMonthsOnset StudyHbA1cT1D.T1DOutcomes
2012
Diabetic Ketoacidosis at Diabetes Onset: Still an All Too Common Threat in Youth
Klingensmith GJ, Tamborlane WV, Wood J, Haller MJ, Silverstein J, Cengiz E, Shanmugham S, Kollman C, Wong-Jacobson S, Beck RW, Consortium P. Diabetic Ketoacidosis at Diabetes Onset: Still an All Too Common Threat in Youth. The Journal Of Pediatrics 2012, 162: 330-334.e1. PMID: 22901739, DOI: 10.1016/j.jpeds.2012.06.058.Peer-Reviewed Original ResearchMeSH KeywordsChildDiabetes Mellitus, Type 1Diabetic KetoacidosisFemaleHumansIncidenceMaleProspective StudiesConceptsSevere diabetic ketoacidosisDiabetic ketoacidosisHemoglobin A1cIncidence of DKAInitial hemoglobin A1cNew-onset T1DPediatric Diabetes ConsortiumDiabetes-associated autoantibodiesLife-threatening complicationsOnset of T1DAfrican American raceType 1 diabetesNon-Hispanic CaucasiansClinical characteristicsEligible subjectsDiabetes onsetMean ageFamily historyPrivate health insuranceInclusion criteriaT1DMultivariate analysisYounger ageDemographic informationHealth insuranceAchievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function
Sherr J, Tamborlane WV, Xing D, Tsalikian E, Mauras N, Buckingham B, White NH, Arbelaez AM, Beck RW, Kollman C, Ruedy K, . Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function. Diabetes Care 2012, 35: 817-820. PMID: 22323414, PMCID: PMC3308298, DOI: 10.2337/dc11-2190.Peer-Reviewed Original ResearchConceptsResidual β-cell functionΒ-cell functionSensor glucose levelsLower glucose variabilityType 1 diabetesGlucose levelsContinuous glucose monitoringT1D participantsGlucose variabilityMean sensor glucose levelPeak C-peptide levelsMixed meal tolerance testTarget A1C levelsC-peptide levelsLong-term T1DShort-term groupNondiabetic groupT1D groupA1c levelsT1D patientsLess hyperglycemiaNondiabetic individualsTolerance testInsulin treatmentHypoglycemia